Breadcrumb

[A19-62] Pembrolizumab (squamous NSCLC, combination chemotherapy) - Addendum to commission A19-31

Overview

Overview

Commission: Commission awarded on 2019-08-05 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Addendum to commission A19-31  [PDF, 288 kB]Further documents
Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Contact address:to the contact form
Linked projects: [A19-31] Pembrolizumab (squamous non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2019-09-19 Addendum to commission A19-31 288 kBPDFdownload file

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.


At a glance

Accompanying information

Federal Joint Committee (G-BA)

2019-09-19 A G-BA decision was published.

G-BA documents on this decision

Press releases

2019-09-19 Pembrolizumab in metastatic NSCLC: now added benefit for subpopulations



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close